These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 12901232

  • 1. Alpha v integrin inhibitors and cancer therapy.
    Tucker GC.
    Curr Opin Investig Drugs; 2003 Jun; 4(6):722-31. PubMed ID: 12901232
    [Abstract] [Full Text] [Related]

  • 2. Integrin targeted drug and gene delivery.
    Wang Z, Chui WK, Ho PC.
    Expert Opin Drug Deliv; 2010 Feb; 7(2):159-71. PubMed ID: 20095940
    [Abstract] [Full Text] [Related]

  • 3. Discrete functional motifs reside within the cytoplasmic tail of alphaV integrin subunit.
    Haas TA.
    Thromb Haemost; 2008 Jan; 99(1):96-107. PubMed ID: 18217140
    [Abstract] [Full Text] [Related]

  • 4. Clinical trials referral resource. Current clinical trials of cilengitide, an alpha(v) antagonist in clinical development as an anticancer agent.
    Colevas AD, Scharf O, Schoenfeldt M.
    Oncology (Williston Park); 2004 Dec; 18(14):1778, 1781-2, 1784. PubMed ID: 15700626
    [No Abstract] [Full Text] [Related]

  • 5. Novel potent and selective alphavbeta3/alphavbeta5 integrin dual antagonists with reduced binding affinity for human serum albumin.
    Raboisson P, Manthey CL, Chaikin M, Lattanze J, Crysler C, Leonard K, Pan W, Tomczuk BE, Marugán JJ.
    Eur J Med Chem; 2006 Jul; 41(7):847-61. PubMed ID: 16697080
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cyclooxygenase-2 inhibition suppresses alphavbeta6 integrin-dependent oral squamous carcinoma invasion.
    Nystrom ML, McCulloch D, Weinreb PH, Violette SM, Speight PM, Marshall JF, Hart IR, Thomas GJ.
    Cancer Res; 2006 Nov 15; 66(22):10833-42. PubMed ID: 17108119
    [Abstract] [Full Text] [Related]

  • 12. Alpha-V-dependent outside-in signaling is required for the regulation of CD44 surface expression, MMP-2 secretion, and cell migration by osteopontin in human melanoma cells.
    Samanna V, Wei H, Ego-Osuala D, Chellaiah MA.
    Exp Cell Res; 2006 Jul 15; 312(12):2214-30. PubMed ID: 16631740
    [Abstract] [Full Text] [Related]

  • 13. Identification of novel short chain 4-substituted indoles as potent alphavbeta3 antagonist using structure-based drug design.
    Raboisson P, Desjarlais RL, Reed R, Lattanze J, Chaikin M, Manthey CL, Tomczuk BE, Marugán JJ.
    Eur J Med Chem; 2007 Mar 15; 42(3):334-43. PubMed ID: 17184884
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Tumor targeting by doxorubicin-RGD-4C peptide conjugate in an orthotopic mouse hepatoma model.
    Kim JW, Lee HS.
    Int J Mol Med; 2004 Oct 15; 14(4):529-35. PubMed ID: 15375578
    [Abstract] [Full Text] [Related]

  • 16. Adenovirus vectors targeting alphaV integrin or heparan sulfate receptors display different distribution of transgene activity after intramuscular injection.
    Cirielli C, Serino F, Straino S, Toietta G, Abeni D, Ventoruzzo G, Orlando G, Mazzanti P, Melillo G, Whickham TJ, Kovesdi I, Biglioli P, Gaetano C, Capogrossi MC.
    J Gene Med; 2004 Mar 15; 6(3):309-16. PubMed ID: 15026992
    [Abstract] [Full Text] [Related]

  • 17. Ligand-based targeted therapy for cancer tissue.
    Das M, Mohanty C, Sahoo SK.
    Expert Opin Drug Deliv; 2009 Mar 15; 6(3):285-304. PubMed ID: 19327045
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.